MA34765B1 - Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci - Google Patents
Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ciInfo
- Publication number
- MA34765B1 MA34765B1 MA36060A MA36060A MA34765B1 MA 34765 B1 MA34765 B1 MA 34765B1 MA 36060 A MA36060 A MA 36060A MA 36060 A MA36060 A MA 36060A MA 34765 B1 MA34765 B1 MA 34765B1
- Authority
- MA
- Morocco
- Prior art keywords
- acid receptor
- receptor antagonists
- compounds
- lysophosphatide acid
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
- C07C53/134—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings monocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/11—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/32—Unsaturated compounds containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/28—Two oxygen or sulfur atoms
- C07D231/30—Two oxygen or sulfur atoms attached in positions 3 and 5
- C07D231/32—Oxygen atoms
- C07D231/36—Oxygen atoms with hydrocarbon radicals, substituted by hetero atoms, attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Abstract
La présente invention concerne des composés antagonistes du(des) récepteur(s) de l'acide lysophosphatidique. L'invention concerne également des compositions pharmaceutiques et des médicaments comprenant les composés décrits ici, ainsi que des procédés d'utilisation de tels antagonistes, seuls ou en association avec d'autres composés, dans le but de traiter des états pathologiques ou des maladies dépendantes de l'acide lysophosphatidique ou induites par celui-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42071610P | 2010-12-07 | 2010-12-07 | |
PCT/US2011/063465 WO2012078593A2 (fr) | 2010-12-07 | 2011-12-06 | Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34765B1 true MA34765B1 (fr) | 2013-12-03 |
Family
ID=45418800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36060A MA34765B1 (fr) | 2010-12-07 | 2013-06-28 | Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci |
Country Status (18)
Country | Link |
---|---|
US (1) | US9272990B2 (fr) |
EP (1) | EP2648714B1 (fr) |
JP (1) | JP2014508111A (fr) |
KR (1) | KR20130126659A (fr) |
CN (1) | CN103347510B (fr) |
AU (1) | AU2011338561A1 (fr) |
BR (1) | BR112013014019A2 (fr) |
CA (1) | CA2820817A1 (fr) |
CL (1) | CL2013001655A1 (fr) |
CO (1) | CO6771417A2 (fr) |
EA (1) | EA201390821A1 (fr) |
IL (1) | IL226491A0 (fr) |
MA (1) | MA34765B1 (fr) |
MX (1) | MX2013006040A (fr) |
PE (1) | PE20140879A1 (fr) |
SG (1) | SG190417A1 (fr) |
WO (1) | WO2012078593A2 (fr) |
ZA (1) | ZA201304159B (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140067048A (ko) | 2011-08-15 | 2014-06-03 | 인터뮨, 인크. | 라이소포스파티드산 수용체 길항제 |
JP2015520201A (ja) * | 2012-06-20 | 2015-07-16 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Lpar拮抗薬としての置換ピラゾール化合物 |
MX2014014710A (es) * | 2012-06-20 | 2015-03-04 | Hoffmann La Roche | Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar). |
KR20150011389A (ko) * | 2012-06-20 | 2015-01-30 | 에프. 호프만-라 로슈 아게 | Lpar 길항제로서 n-아릴트라이아졸 화합물 |
CN104684584A (zh) * | 2012-07-02 | 2015-06-03 | 费卜卢斯坦丁公司 | Gpbp-1的抑制及其治疗用途 |
RU2015110006A (ru) * | 2012-09-05 | 2016-10-27 | Ф. Хоффманн-Ля Рош Аг | Замещенные соединения цианопиразола в качестве антагонистов лизофосфатидной кислоты |
WO2014053450A1 (fr) | 2012-10-02 | 2014-04-10 | Bayer Cropscience Ag | Composés hétérocycliques utilisés comme pesticides |
EP2940013B1 (fr) | 2012-12-28 | 2018-02-21 | Ube Industries, Ltd. | Composé hétérocyclique substitué par un halogène |
TW201437200A (zh) * | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
CN105102448B (zh) | 2013-02-28 | 2018-03-06 | 百时美施贵宝公司 | 作为rock1和rock2抑制剂的苯基吡唑衍生物 |
TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物 |
KR102090231B1 (ko) * | 2013-03-15 | 2020-03-17 | 에피젠 바이오싸이언시즈, 아이엔씨. | 질환의 치료에 유용한 헤테로환식 화합물 |
JP2014231508A (ja) * | 2013-05-02 | 2014-12-11 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物 |
EA038294B1 (ru) * | 2013-05-24 | 2021-08-05 | Эпиджен Байосайенсиз, Инк. | Гетероциклические соединения, применимые в лечении заболеваний |
ES2824801T3 (es) | 2014-06-27 | 2021-05-13 | Ube Industries | Sal de compuesto heterocíclico sustituido con halógeno |
WO2016046782A1 (fr) * | 2014-09-26 | 2016-03-31 | Glenmark Pharmaceuticals S.A. | Composés imidazole biaryle en tant qu'inhibiteurs de la s-nitrosoglutathion réductase |
WO2016197009A1 (fr) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles pour le traitement de maladies liées à la démyélinisation |
AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
WO2018106646A1 (fr) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles pour traiter des maladies démyélinisantes |
WO2018106643A1 (fr) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Azoles hétérocycliques pour le traitement de maladies de démyélinisation |
WO2018106641A1 (fr) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles pour le traitement de maladies démyélinisantes |
WO2019041340A1 (fr) * | 2017-09-04 | 2019-03-07 | Eli Lilly And Company | Composés inhibiteurs du récepteur 1 de l'acide lysophosphatidique (lpar1) |
AU2018388482A1 (en) | 2017-12-19 | 2020-07-30 | Bristol-Myers Squibb Company | Pyrazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
US11312706B2 (en) | 2017-12-19 | 2022-04-26 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as LPA antagonists |
WO2019126093A1 (fr) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Azines triazoles d'acide cyclohexyle utilisées en tant qu'antagonistes de lpa |
JP2021506878A (ja) | 2017-12-19 | 2021-02-22 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Lpaアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン |
WO2019126098A1 (fr) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Acides carbamoyle cyclohexyliques à liaison o pyrazole utilisés en tant qu'antagonistes de lpa |
US11261180B2 (en) | 2017-12-19 | 2022-03-01 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as LPA antagonists |
JP7212047B2 (ja) | 2017-12-19 | 2023-01-24 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール |
BR112020012177A2 (pt) | 2017-12-19 | 2020-11-24 | Bristol-Myers Squibb Company | azóis triazóis do ácido ciclo-hexílico como antagonistas de lpa |
US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
ES2925626T3 (es) | 2017-12-19 | 2022-10-19 | Bristol Myers Squibb Co | Acidos isoxazol-O-carbamoilciclohexílicos como antagonistas de LPA |
CA3121202A1 (fr) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Composes pyrrole et pyrazole et leurs procedes d'utilisation |
CN112574201B (zh) * | 2019-09-29 | 2024-04-19 | 四川科伦博泰生物医药股份有限公司 | 芳基胺类化合物、包含其的药物组合物及其制备方法和用途 |
US11548871B2 (en) | 2019-11-15 | 2023-01-10 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
WO2021107125A1 (fr) * | 2019-11-29 | 2021-06-03 | 小野薬品工業株式会社 | Composé ayant une activité agoniste du récepteur de l'acide lysophosphatidique et utilisation pharmaceutique dudit composé |
CN114786771A (zh) * | 2019-12-12 | 2022-07-22 | 奇斯药制品公司 | 作为lpa受体2抑制剂的喹唑啉衍生物 |
US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
TW202344504A (zh) | 2020-06-03 | 2023-11-16 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
TW202342017A (zh) | 2022-02-25 | 2023-11-01 | 美商洛子峰生物有限公司 | 用於治療與lpa受體活性相關的病狀的化合物及組合物 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
JPS60239743A (ja) | 1984-05-15 | 1985-11-28 | Canon Inc | 記録媒体 |
JPS6137885A (ja) | 1984-07-31 | 1986-02-22 | Canon Inc | El素子 |
US5011692A (en) | 1985-12-28 | 1991-04-30 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5972240A (en) | 1994-07-15 | 1999-10-26 | Seiko Epson Corporation | Liquid crystal composite material and liquid crystal display device(s) which use them |
GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
DE19907904A1 (de) | 1999-02-24 | 2000-08-31 | Clariant Gmbh | Verfahren zur Herstellung von [1,1':4',1"]-Terphenylverbindungen |
DE60226355T2 (de) | 2001-02-08 | 2009-05-28 | Seimi Chemical Co. Ltd., Chigasaki | Flüssigkristallzusammensetzung, welche eine optisch aktive Verbindung enthält, und elektrooptisches Flüssigkristallelement |
DE60234318D1 (de) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
CA2446380A1 (fr) * | 2001-05-08 | 2002-11-14 | Yale University | Composes proteomimetiques et procedes correspondants |
PL1638551T3 (pl) | 2003-05-19 | 2012-05-31 | Irm Llc | Związki i kompozycje immunosupresyjne |
US20050245543A1 (en) | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
JP2009504575A (ja) | 2005-08-11 | 2009-02-05 | メルク フロスト カナダ リミテツド | 新規の置換された1,2,3,−トリアゾリルメチル−ベンゾチオフェン又は−インドール並びにロイコトリエン生合成阻害剤としてのそれらの使用 |
US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
JP5092236B2 (ja) | 2005-12-20 | 2012-12-05 | 旭硝子株式会社 | 重合性液晶性組成物、高分子液晶、光学素子、及びターフェニル誘導体 |
KR101223895B1 (ko) | 2006-01-06 | 2013-01-17 | 제이엔씨 주식회사 | 알케닐을 갖는 모노 불소화테르페닐 화합물, 액정 조성물및 액정 표시 소자 |
MX2008009475A (es) | 2006-01-23 | 2008-10-20 | Amira Pharmaceuticals Inc | Inhibidores triciclicos de 5-lipoxigenasa. |
GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
JP5399745B2 (ja) | 2009-03-12 | 2014-01-29 | Jx日鉱日石エネルギー株式会社 | 多孔性金属錯体、多孔性金属錯体の製造方法及びガス貯蔵方法 |
EP2462128B1 (fr) | 2009-08-04 | 2016-09-21 | Amira Pharmaceuticals, Inc. | Composés en tant qu'antagonistes du récepteur de l'acide lysophosphatidique |
GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
WO2011159550A2 (fr) | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Antagoniste du récepteur de l'acide lysophosphatidique et ses utilisations |
WO2011159633A1 (fr) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Formulations inhalables d'antagonistes de récepteur d'acide lysophosphatidique |
ES2674174T3 (es) | 2010-12-07 | 2018-06-27 | Bristol-Myers Squibb Company | Antagonista de LPA1 policíclico y usos del mismo |
-
2011
- 2011-12-06 PE PE2013001366A patent/PE20140879A1/es not_active Application Discontinuation
- 2011-12-06 EP EP11802233.4A patent/EP2648714B1/fr not_active Not-in-force
- 2011-12-06 WO PCT/US2011/063465 patent/WO2012078593A2/fr active Application Filing
- 2011-12-06 KR KR1020137017645A patent/KR20130126659A/ko not_active Application Discontinuation
- 2011-12-06 SG SG2013040795A patent/SG190417A1/en unknown
- 2011-12-06 CN CN201180066991.8A patent/CN103347510B/zh not_active Expired - Fee Related
- 2011-12-06 AU AU2011338561A patent/AU2011338561A1/en not_active Abandoned
- 2011-12-06 BR BR112013014019A patent/BR112013014019A2/pt not_active IP Right Cessation
- 2011-12-06 EA EA201390821A patent/EA201390821A1/ru unknown
- 2011-12-06 MX MX2013006040A patent/MX2013006040A/es not_active Application Discontinuation
- 2011-12-06 US US13/992,053 patent/US9272990B2/en active Active
- 2011-12-06 CA CA2820817A patent/CA2820817A1/fr not_active Abandoned
- 2011-12-06 JP JP2013543256A patent/JP2014508111A/ja active Pending
-
2013
- 2013-05-21 IL IL226491A patent/IL226491A0/en unknown
- 2013-06-06 ZA ZA2013/04159A patent/ZA201304159B/en unknown
- 2013-06-07 CL CL2013001655A patent/CL2013001655A1/es unknown
- 2013-06-28 MA MA36060A patent/MA34765B1/fr unknown
- 2013-07-04 CO CO13158409A patent/CO6771417A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CN103347510B (zh) | 2015-11-25 |
JP2014508111A (ja) | 2014-04-03 |
EA201390821A1 (ru) | 2013-10-30 |
PE20140879A1 (es) | 2014-08-06 |
CA2820817A1 (fr) | 2012-06-14 |
KR20130126659A (ko) | 2013-11-20 |
CL2013001655A1 (es) | 2014-04-04 |
MX2013006040A (es) | 2013-08-26 |
IL226491A0 (en) | 2013-07-31 |
ZA201304159B (en) | 2014-12-23 |
CN103347510A (zh) | 2013-10-09 |
EP2648714B1 (fr) | 2015-11-18 |
SG190417A1 (en) | 2013-07-31 |
AU2011338561A1 (en) | 2013-07-25 |
WO2012078593A3 (fr) | 2012-08-02 |
US9272990B2 (en) | 2016-03-01 |
CO6771417A2 (es) | 2013-10-15 |
US20130253004A1 (en) | 2013-09-26 |
EP2648714A2 (fr) | 2013-10-16 |
WO2012078593A2 (fr) | 2012-06-14 |
BR112013014019A2 (pt) | 2016-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34765B1 (fr) | Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci | |
MA32226B1 (fr) | Compositions et leurs procedes de preparation et d'utilisation | |
MA34449B1 (fr) | Formulation de poudre seche comprenant un inhibiteur de phosphodiesterase | |
MA32131B1 (fr) | Antagonistes aminoalkylbiphényle n, n' disubstitués des récepteurs d2 de la prostaglandine | |
MA38183A1 (fr) | Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase | |
EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
MA39033A1 (fr) | Formes solides d'acide {[5-(3-chlorophényl)-3-hydroxypyridine-2-carbonyl] amino}acétique, compositions et leurs utilisations | |
MA32230B1 (fr) | Formes cristallines et deux formes solvatées de lactates de 4-amino-5-fluoro -3-[5-(4-méthylpipérazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one | |
MA38391A1 (fr) | Dérivés de pyridinyl et triazolone pyridinyl de fusion | |
MA33299B1 (fr) | Nouvelle formulation de naproxène | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
MA35869B1 (fr) | Composés imidazopyrrolidinone | |
MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
MA33296B1 (fr) | Nouvelle formulation d'indométhacine | |
TN2012000192A1 (fr) | N1-pyrazolospirocetones inhibitrices d'acetyl-coa-carboxylase | |
MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
MA34819B1 (fr) | Dérivés bicyclo[3.2.1]octylamide et leurs utilisations | |
BR112013008140A8 (pt) | "compostos imidazotriazinona". | |
MA35443B1 (fr) | Composes benzofuranes pour le traitement d'infections par le virus de l'hepatite c | |
MA30207B1 (fr) | Modulateurs des recepteurs de la progesterone a base d'indole sulfonamide | |
MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
MA34650B1 (fr) | Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane | |
MA37891A1 (fr) | Alcoxypyrazoles comme activateurs de guanylate cyclase soluble | |
MA35187B1 (fr) | Composés ayant une activité antagoniste d'un récepteur muscarinique et agoniste d'un récepteur béta2 adrénergique | |
MA33419B1 (fr) | Composés et compositions pour le traitement de maladies parasitaires |